Biomarin Pharmaceutical Inc (BMRN) Stock Price & Analysis
Biomarin Pharmaceutical Inc (BMRN) rose 2.40% to USD 57.91 as of June 9, 2026 at 23:44 UTC, according to Nexqual real-time market data.
BMRN last closed at USD 56.55; the session ranged USD 56.85–58.11 on volume of 2,767,016 shares. Market capitalization is $11.19B, with a 52-week range of USD 49.26–66.28 (NMS). Source: Nexqual, June 9, 2026 at 23:44 UTC.
Key Statistics (as of June 9, 2026 at 23:44 UTC)
| Price | USD 57.91 |
|---|---|
| Change | ▲ 2.40% (up) |
| Previous Close | USD 56.55 |
| Open | USD 57.41 |
| Day Range | USD 56.85 – 58.11 |
| 52-Week Range | USD 49.26 – 66.28 |
| Volume | 2,767,016 shares |
| Market Cap | $11.19B |
| Exchange | NMS |
Technical Analysis (BMRN)
Nexqual's technical model rates BMRN "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 23:44 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.34 (neutral) |
| vs SMA50 | Above (USD 54.37) |
| MACD | 0.77 (positive) |
Analyst Ratings (BMRN)
Wall Street analysts rate BMRN "Buy" based on 26 analysts, with a mean price target of USD 87.85 (range USD 50–120), per Nexqual as of June 9, 2026 at 23:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 87.85 |
| High Target | USD 120 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 20 / 6 / 0 |
Earnings (BMRN)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 0.96 |
| Revenue Estimate | $933.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.76 vs est 0.91 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.56 ▼ miss |
| 2025-09-30 | USD 0.12 vs est 0.34 ▼ miss |
| 2025-06-30 | USD 1.44 vs est 1.03 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Financials & Fundamentals (BMRN)
| Total Revenue | $3.24B |
|---|---|
| Revenue Growth (YoY) | +2.80% |
| Gross Margin | +51.16% |
| Operating Margin | +18.00% |
| Profit Margin | +8.29% |
| ROE | +4.48% |
| Debt / Equity | 23.17 |
| Current Ratio | 5.81 |
| Total Cash | $2.22B |
| Total Debt | $1.44B |
| Free Cash Flow | $459.42M |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Financial Health Score (BMRN)
Nexqual rates Biomarin Pharmaceutical Inc's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:44 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 51%, operating 18% |
| Balance Sheet | Strong — $2.22B cash vs $1.44B debt, net cash position |
| Cash Flow | Solid — FCF $459M, 14% margin |
| Efficiency | Weak — ROE 4%, ROA 4.5% |
Ownership (BMRN)
| Insider Ownership | +0.35% |
|---|---|
| Institutional Ownership | +102.70% |
| Shares Outstanding | 193.28M |
| Float | 192.09M |
| Short % of Float | +5.89% |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
Leadership (BMRN)
Biomarin Pharmaceutical Inc is led by Alexander Hardy (age 56), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:44 UTC.
| President, CEO & Director | Alexander Hardy (age 56) |
|---|---|
| CFO & Executive VP of Finance | Brian R. Mueller (age 51) |
| Executive VP & CTO | C. Greg Guyer (age 63) |
| Chief Scientific Officer & Senior VP of Research and Early Development | Kevin Eggan |
| Executive Vice President, Chief Digital & Information Officer | Arpit Dave |
Major Backers & Investors (BMRN)
Notable institutional backers of Biomarin Pharmaceutical Inc include Dodge & Cox Inc., Primecap Management Company, AQR Capital Management, LLC, according to Nexqual as of June 9, 2026 at 23:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 12.58% |
| Primecap Management Company | 7.34% |
| AQR Capital Management, LLC | 3.97% |
| Viking Global | 3.65% |
| Citadel | 2.33% |
| Capital Group | 1.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.93% |
| BlackRock | 13.61% |
| State Street | 3.77% |
| Geode Capital | 1.98% |
Source: Nexqual, June 9, 2026 at 23:44 UTC.
From Biomarin Pharmaceutical Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
- It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease.
- The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.
- It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INCY | Incyte Corporation | USD 103.23 | ▲ 0.83% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 445.77 | ▼ 0.24% |
| REGN | Regeneron Pharmaceuticals, Inc. | USD 616.18 | ▼ 3.03% |
| BIIB | Biogen Inc. | USD 199.1 | ▲ 1.92% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:44 UTC. This page is informational and not investment advice.